Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of p53 in transcriptional repression of SVCT2.
Kim EH, Koh DI, Ryu YS, Park SS, Hong SW, Moon JH, Shin JS, Kim MJ, Kim DY, Hong JK, Jeong HR, Yun H, Shin JY, Kim J, Park YS, Kim DM, Jin DH. Kim EH, et al. Among authors: ryu ys. Mol Biol Rep. 2021 Feb;48(2):1651-1658. doi: 10.1007/s11033-021-06179-2. Epub 2021 Feb 12. Mol Biol Rep. 2021. PMID: 33580460
Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
Hong SW, Shin JS, Moon JH, Jung SA, Koh DI, Ryu Y, Park YS, Kim DY, Park SS, Hong JK, Kim EH, Kim MJ, Jeong HR, Bae IH, Ahn YG, Suh KH, Cho IJ, Kang JS, Hong YS, Lee JS, Jin DH, Kim TW. Hong SW, et al. Among authors: ryu y. Invest New Drugs. 2020 Dec;38(6):1696-1706. doi: 10.1007/s10637-020-00956-9. Epub 2020 May 27. Invest New Drugs. 2020. PMID: 32462369
CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK/STAT Pathway in Colorectal Cancer.
Hong JK, Kim DY, Shin JS, Ryu YS, Moon JH, Koh DI, Lee S, Lee J, Lee WJ, Lee EY, Jung SA, Kim SC, Yu HN, Kim MJ, Hong SW, Park SS, Jung J, Kim SM, Kim EH, Jeong HR, Gong JH, Kim J, Kim TW, Jin DH. Hong JK, et al. Among authors: ryu ys. Anticancer Res. 2022 Apr;42(4):1813-1819. doi: 10.21873/anticanres.15657. Anticancer Res. 2022. PMID: 35346999
Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy.
Kim J, Koh DI, Lee M, Park YS, Hong SW, Shin JS, Lee MS, Kim MH, Lee JH, Jeong J, Bae S, Hong JK, Jeong HR, Ryu YS, Kim SM, Choi M, Kim H, Ryu H, Hur SC, Park J, Hur DY, Jin DH. Kim J, et al. Among authors: ryu ys. Cell Death Differ. 2023 Dec;30(12):2491-2507. doi: 10.1038/s41418-023-01235-9. Epub 2023 Nov 6. Cell Death Differ. 2023. PMID: 37926711
The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy.
Koh DI, Lee M, Park YS, Shin JS, Kim J, Ryu YS, Lee JH, Bae S, Lee MS, Hong JK, Jeong HR, Choi M, Hong SW, Kim DK, Lee HK, Kim B, Yoon YS, Jin DH. Koh DI, et al. Among authors: ryu ys. Cancer Immunol Res. 2024 Apr 2;12(4):491-507. doi: 10.1158/2326-6066.CIR-23-0817. Cancer Immunol Res. 2024. PMID: 38289363
101 results